University Hospital Heidelberg
klinikum.uni-heidelberg.deLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
176
Active
54
Phase 3
5
Total enrollment
117,315
Pipeline matrix
Showing 12 of 12 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Sacituzumab Govitecan | — | — | — | — | — | 1 | |
| Physicians Choice (PhC). | — | — | — | — | — | 1 | |
| CETEG | — | — | — | — | — | 1 | |
| PCV | — | — | — | — | — | 1 | |
| Cyclosporine A | — | — | — | — | — | 1 | |
| CD19.CAR T Cells | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Signifor | — | — | — | — | — | 1 | |
| Nivolumab and Entinostat | — | — | — | — | — | 1 | |
| Atezolizumab 1200 mg abs day 1 q22 | — | — | — | — | — | 1 |
Next readouts
- 2024-11-30
- 2026-06-30
- 2026-12-31
- 2027-02
- 2027-10
- 2028-01
- 2028-08-01
- 2033-03-31
Top conditions
- Ischemic Stroke9
- Coronary Artery Disease7
- Cancer6
- Atrial Fibrillation5
- Brain Metastases3
- Acute Ischemic Stroke3
- Head and Neck Cancer3
- Prostate Cancer3
Frequently asked questions about University Hospital Heidelberg
- How many clinical trials does University Hospital Heidelberg have on ClinicalTrials.gov?
- University Hospital Heidelberg is listed as the lead sponsor on 176 clinical trials in ClinicalTrials.gov, 54 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital Heidelberg's trials are in Phase 3?
- 5 of University Hospital Heidelberg's trials are in Phase 3, spread across 12 active drug programs.
- What therapeutic areas does University Hospital Heidelberg focus on?
- University Hospital Heidelberg's most-studied conditions on ClinicalTrials.gov are Ischemic Stroke, Coronary Artery Disease, Cancer, Atrial Fibrillation, Brain Metastases.
- When are University Hospital Heidelberg's next clinical trial readouts?
- University Hospital Heidelberg has 8 upcoming primary-completion readouts tracked here; the soonest is “Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC”, expected around 2024-11-30.